SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

OBJECTIVES: The primary objective is to evaluate the efficacy of camostat to prevent respiratory deterioration in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Secondary objectives include assessment of the ability of camostat to reduce the requirement for Cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Halford, Sarah, Wan, Susan, Dragoni, Ilaria, Silvester, Julie, Nazarov, Bobojon, Anthony, Daniel, Anthony, Suzie, Ladds, Emma, Norrie, John, Dhaliwal, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375281/
https://www.ncbi.nlm.nih.gov/pubmed/34412682
http://dx.doi.org/10.1186/s13063-021-05461-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375281/
https://www.ncbi.nlm.nih.gov/pubmed/34412682
http://dx.doi.org/10.1186/s13063-021-05461-9

Ejemplares similares